













{"id":643,"date":"2018-09-17T16:22:38","date_gmt":"2018-09-17T15:22:38","guid":{"rendered":"http:\/\/design4paper.com\/vipartners-test-live-test-live\/?p=643"},"modified":"2020-11-09T16:25:40","modified_gmt":"2020-11-09T15:25:40","slug":"sequana-medical-reports-positive-data-on-use-of-the-alfapump-in-malignant-ascites-patients-at-the-international-gynecologic-cancer-society","status":"publish","type":"post","link":"https:\/\/design4paper.com\/vipartners-test-live\/sequana-medical-reports-positive-data-on-use-of-the-alfapump-in-malignant-ascites-patients-at-the-international-gynecologic-cancer-society\/","title":{"rendered":"Sequana Medical reports positive data on use of the alfapump\u00ae in malignant ascites patients at the International Gynecologic Cancer Society"},"content":{"rendered":"\n<p>Sequana Medical AG (\u201cSequana Medical\u201d), a&nbsp;commercial stage medical device company focused on the development of innovative treatment&nbsp;solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance&nbsp;disorders, announces today positive findings from its Retrospective Malignant Ascites Study.<\/p>\n\n\n\n<p>The study retrospectively evaluated 17 patients with malignant ascites that had been implanted with the&nbsp;alfapump\u00ae&nbsp;in centres across Europe. The study demonstrated that the alfapump\u00ae&nbsp;was effective in&nbsp;treating palliative patients with malignant ascites and improving their quality of life.<\/p>\n\n\n\n<p>The findings of the study were presented by Principal Investigator, Christina Fotopoulou MD, PhD,&nbsp;Imperial College London at the 17th&nbsp;Biennial Meeting of the International Gynecologic Cancer Society&nbsp;that was held from 14-16 September in Kyoto, Japan.<\/p>\n\n\n\n<p>Prof. Dr. Christina Fotopoulou at Imperial College London commented: \u201cThe alfapump\u00ae&nbsp;is a novel&nbsp;strategy offering a new opportunity for patients with refractory malignant ascites to have an improved&nbsp;quality of life and a lower need for hospitalisation, so that they can spend more time outside of a hospital&nbsp;environment. It is a very promising, minimally invasive technology that has the potential to significantly&nbsp;improve the quality of life of patients in a very difficult phase of their lives.\u201d<\/p>\n\n\n\n<p>Ian Crosbie, Chief Executive Officer of Sequana Medical, added: \u201cThese data build upon our&nbsp;extensive clinical and commercial experience with the alfapump\u00ae&nbsp;in liver refractory ascites and support&nbsp;our growth strategy in malignant ascites. Patients with malignant ascites have a poor prognosis where&nbsp;the impact of ascites on their quality of life is significant, often reducing their ability to withstand further&nbsp;cancer treatments. There is therefore a high unmet need for a therapy that manages malignant ascites&nbsp;and improves patients\u2019 quality of life. We believe that these data demonstrate the compelling potential&nbsp;of the alfapump\u00ae&nbsp;to improve clinical outcomes for malignant ascites patients.\u201d<\/p>\n\n\n\n<p>The data will also be presented at the 68th&nbsp;Annual Meeting of the Society of Pelvic Surgeons being held&nbsp;from 23-29 September 2018 in Bucharest, Romania.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sequana Medical AG (\u201cSequana Medical\u201d), a&nbsp;commercial stage medical device company focused on the development of innovative treatment&nbsp;solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance&nbsp;disorders, announces today positive findings from its Retrospective Malignant Ascites Study. The study retrospectively evaluated 17 patients with malignant ascites that had been implanted with<a class=\"moretag\" href=\"https:\/\/design4paper.com\/vipartners-test-live\/sequana-medical-reports-positive-data-on-use-of-the-alfapump-in-malignant-ascites-patients-at-the-international-gynecologic-cancer-society\/\"> Read the full article&#8230;<\/a><\/p>\n","protected":false},"author":3,"featured_media":330,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":[],"categories":[8,3,5],"tags":[],"_links":{"self":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts\/643"}],"collection":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/comments?post=643"}],"version-history":[{"count":1,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts\/643\/revisions"}],"predecessor-version":[{"id":644,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/posts\/643\/revisions\/644"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/media\/330"}],"wp:attachment":[{"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/media?parent=643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/categories?post=643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/design4paper.com\/vipartners-test-live\/wp-json\/wp\/v2\/tags?post=643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}